Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protecting the future generation through science and HBV vaccination.

Hepatology (Baltimore, Md.)·2025
Same author

Accurate identification and risk-stratification of HBeAg-negative indeterminate phase of chronic hepatitis B: Not all shades of grey are the same.

Hepatology (Baltimore, Md.)·2025
Same author

Is Sustained Virologic Response to Direct-acting Antivirals a Valid Surrogate Endpoint for Clinical Outcomes of Hepatitis C?

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2020
Same author

Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference<sup>‡</sup>.

Journal of hepatology·2019
Same author

Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.

Hepatology (Baltimore, Md.)·2019
Same author

How Do We Determine Whether a Functional Cure for HBV Infection Has Been Achieved?

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2019

Related Experiment Video

Updated: May 16, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

HCV NS5A inhibitors in development.

Anna Suk-Fong Lok1

  • 1Division of Gastroenterology and Hepatology, University of Michigan Health System, University of Michigan, Ann Arbor, 48109, USA. aslok@umich.edu

Clinics in Liver Disease
|November 27, 2012
PubMed
Summary

Daclatasvir effectively inhibits hepatitis C virus (HCV) replication. Combination therapies including daclatasvir show high response rates in patients with genotype 1 HCV infection.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) NS5A protein is crucial for viral replication.
  • Daclatasvir (DCV) is a novel inhibitor targeting the HCV NS5A replication complex.
  • DCV exhibits potent antiviral activity but has a limited barrier to resistance.

Purpose of the Study:

  • To evaluate the efficacy of daclatasvir in combination therapies for hepatitis C virus infection.
  • To assess treatment outcomes in different patient populations, including treatment-naïve and treatment-experienced individuals.

Main Methods:

  • Clinical trials were conducted to assess triple and quadruple therapy regimens.
  • Regimens included daclatasvir, pegylated interferon, ribavirin, and asunaprevir (NS3 protease inhibitor).

More Related Videos

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Related Experiment Videos

Last Updated: May 16, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

  • Patient outcomes were measured by early virologic response and sustained virologic response rates.

    • Main Results:

    • Triple therapy (DCV + pegylated interferon + ribavirin) achieved high early virologic response in treatment-naïve genotype 1 HCV patients.
    • Quadruple therapy (DCV + asunaprevir + pegylated interferon + ribavirin) demonstrated high sustained virologic response in genotype 1 prior null responders.
    • Daclatasvir-based regimens showed significant antiviral efficacy across different treatment scenarios.

    Conclusions:

    • Daclatasvir-based therapies are effective for treating hepatitis C virus genotype 1 infection.
    • Combination therapy with daclatasvir offers promising outcomes for both treatment-naïve and difficult-to-treat patient groups.
    • Further research may explore optimizing daclatasvir regimens for HCV eradication.